Recent Transactions

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies

Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

Advised Det Norske Veritas on its merger with Germanischer Lloyd to create the third largest player in the Testing, Inspection and Certification industry, focused on ship classification, oil & gas and energy

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

Advised Antin Infrastructure Partners on the acquisition of a portfolio of solar PV power plants in Italy

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research

Advised Kelda Group plc, a leading provider of water and waste water services in the UK, on a recommended cash offer from a consortium of international infrastructure investors